Investors have run back to the stock after promising clinical results.
The business reported an operating loss of $77 million in the first nine months of fiscal 2019.
These income stocks can make your retirement funds go even further.
Inject a little (or a lot) of growth into your portfolio with these three companies.
The company has revised guidance in each of the last four quarters, but it continues to outperform expectations.
The clinical-stage biopharma announced changes to its lead pipeline program. Will it be enough?
Investors looking to grow their nest egg should give these three stocks a closer look.
The lab hardware company reported fiscal third-quarter 2019 operating results.
The gold miner delivered a solid performance in the first half of 2019, but investors are remaining cautious.
A sluggish end to fiscal 2019 and weaker-than-expected guidance for the year ahead aren't instilling much confidence in investors.
The genetic testing company reported fiscal 2019 operating results and told investors that regulators want changes to an important product.
The fuel cell company told investors to expect no growth in 2020.
Solid clinical results were just what the struggling pharma company needed.
Higher input costs and lower selling prices weighed on the business throughout the first half of 2019. Can the biodiesel leader weather the storm?
Should you follow in their footsteps?
Investors were anticipating weak second-quarter 2019 operating results. They were right.
A Wall Street analyst soured on the LNG exporter-in-waiting and downgraded the stock.
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
The stock cooled off along with its cannabis-based peers.
The enzyme engineering platform has $93 million in cash and no shortage of growth opportunities. Can it execute?